Friday, May 1, 2026

Beyond Missiles: How North Korea is Using Art to Project Power with Russia

Over 100 North Korean propaganda artworks depicting troops in Ukraine were showcased at a Moscow exhibition, highlighting military ties with Russia.

North Korea’s Nuclear Stance: What Kim Jong Un’s Recent Speech Means for U.S. Relations

South Korea supports resuming North Korea-U.S. dialogue, emphasizing creative approaches to reduce tensions and build trust.

New Obesity Pill Could End Wegovy’s Reign, Offering Faster and Safer Results

Ildong's ID110521156 shows promise as an affordable GLP-1 obesity drug with fewer side effects, aiming to transform the treatment landscape.

Tag: CDMO

North KoreaKoreaKimMilitarySouth KoreaAImarketrelationsInternational

Samsung Biologics Strengthens Global Partnerships at Decat Week 2026: Key Insights and Strategies

Samsung Biologics aims to enhance global partnerships at J.P. Morgan's Healthcare Conference 2026, showcasing its CDMO strengths.

HLB Pep Signs Deal with Japan’s ReproCELL to Supply Customized Neoantigen Peptides — The Future of Precision Medicine?

HLB PEP partners with Reprocell to supply customized neo-antigen peptides for personalized cancer treatment, targeting global markets.

Estipam Secures Record 897 Billion KRW Contract for Oligonucleotide Raw Materials: What This Means for the Asian Market

ST Pharm secures a record 89.7 billion KRW contract for oligonucleotide ingredients, enhancing its global market position.

Lotte Biologics at DCAT Week 2026: Unveiling Strategic Collaborations in Global CDMO

Lotte Biologics will attend DCAT Week in New York to pursue global CDMO partnerships and showcase its production capabilities.

Samsung Biologics CEO John Rim Poised for Third Term: What This Means for the Global CDMO Market in 2026

John Rim of Samsung Biologics aims for a third term, leading record growth and expansion into next-gen therapies amid global challenges.

Samsung Biologics: How a 56 Billion USD CDMO Leader is Shaping the Future of Biopharmaceuticals

Samsung Biologics is evolving as a leading CDMO, targeting a production capacity of 1.32M liters by 2030 after its spin-off from Bioepis.

ST Pharm’s Record Growth: How RNA-Based Therapies Are Transforming the CDMO Market in 2026

ST Pharm reports record growth in oligonucleotide CDMO, driven by rising demand for RNA-based treatments for chronic diseases.

Samsung Biologics Unveils Three-Pillar Growth Strategy: How Capacity, Portfolio, and Global Expansion Shape 2026

Samsung Biologics outlines a growth strategy focused on production, portfolio, and global expansion to enhance its CDMO position.

GAME OVER: Samsung Biologics Declares War With ‘ExellenS’—A Standard That Kills All Biotech Competition

Samsung Biologics launches ExellenS in Europe, enhancing biopharmaceutical production with standardized quality and efficiency.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.